EpiCheck and Short-term Intensive Chemoresection in NMIBC

Aarhus University Hospital22 enrolled

Overview

The aim of this explorative study is to evaluate whether EpiCheck can be used as a predictor of tumour response to short-term, intensive chemoresection with Mitomycin.

The study will be conducted as an exploratory, prospective observational study. Participants consists of patients referred to short-term, intensive chemoresection due to recurrent NMIBC. The treatment adhere to the regimen described in the NICSA trial with the ClinicalTrials.gov identifier NCT03348969. Treatment consists of short-term, intensive chemoresection with Mitomycin; 40 mg is administered intravesically three times a week for two weeks. To evaluate tumour response, an early cystoscopy is performed in the outpatient clinic one to two months after treatment completion. No visible tumour and residual tumour with benign histology is considered complete response. Residual tumour tissue with neoplastic histology is considered incomplete response and will be treated with TURBT or tumour fulguration. Subsequently patients continue a standardized follow-up program as Danish guidelines prescribe which is initiated after four months.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bladder Cancer

Interventions

EpiCheckDEVICE

If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a known history of Ta HG with recurrent disease * Patients referred to short-term, intensive chemoresection * Patients older than 18 years Exclusion Criteria: * Known allergy or intolerance to Mitomycin * Incontinence or small bladder capacity (\< 100 mL) * Previous pelvic radiation therapy

Locations (1)

Aarhus University Hospital

Aarhus, Denmark

RECRUITING

Outcomes

Primary Outcomes

EpiCheck result

Number of patients with accordance between EpiCheck score and clinical findings at the time of evaluation cystoscopy

Time frame: One to two months after short-term, intensive chemoresection

Secondary Outcomes

EpiCheck result 2

Number of patients with discrepancy between EpiCheck score and clinical findings at the time of cystoscopy

Time frame: One to two months after short-term, intensive chemoresection

EpiCheck result 3

Trend of the EpiCheck test over time (increase/decrease/stable score) and its correlation to complete/incomplete tumour response

Time frame: One to two months after short-term, intensive chemoresection

Urine cytology

Sensitivity, specificity, negative and positive predictive value for urine cytology

Time frame: One to two months after short-term, intensive chemoresection

Central Contacts

Maria S Lindgren, MD

CONTACT

30915431 maalin@rm.dk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.